engineered CAR (iC9/CAR19/IL-15 T) T cells with a greater expansion potential (10-fold greater in vitro and 3- to 15-fold greater in vivo), greater persistence, and stronger antitumor effects in a SCID lymphoma human xenograft model (37). The gene discussed is IL15; the disease is lymphoma.